Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A user reports persistent sexual side effects three months after stopping finasteride, despite a healthy lifestyle and supplements. They express concern over the lack of libido and infrequent erections.

The user's hairline is receding despite using finasteride for 7-8 years and minoxidil for 1 year, with inconsistent usage. They are considering other treatments like microneedling.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The user is trying a new hair loss regimen including Spirolactone, Finasteride, oral Minoxidil, microneedling, and various supplements. They are experiencing increased shedding and seeking advice on microneedling and treatment effectiveness.

The user experienced significant hair loss on the scalp, eyebrows, eyelashes, and pubic area, along with itchy, flaky skin and red patches. They have a history of eczema and dermatitis and suspect that stopping shampoo use and taking Ritalin may have contributed to the issue.

Treating hair loss with finasteride, minoxidil, RU58841, and Nizoral, and the progress of this treatment over a period of six months.

The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.

KX-826 did not maintain hair loss prevention for users. Some switched to Pyrilutamide but returned to Minoxidil and RU58841 due to worsening conditions.

People are frustrated with hair loss treatments like finasteride, minoxidil, and dutasteride, with mixed results and side effects. Some users suggest trying different combinations or doses, while others express disappointment and hope for a cure.

The user experienced significant hair shedding while using finasteride and oral minoxidil but found that the shedding eventually stopped, and hair returned to its previous state. They advise patience, continuing medication, and maintaining good nutrition, including Vitamin D.

The user has been using finasteride for 16 months, minoxidil for 11 months, and started microneedling 2 months ago, experiencing shedding phases. They are questioning whether they are experiencing miniaturization or regrowth.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

A user has been on 1mg finasteride daily for 10 months, initially seeing great results, but started shedding heavily again at the 7-month mark. They are considering whether to continue with finasteride or switch to dutasteride.

A user saw no results from using minoxidil and microneedling for 1.5 years and is considering trying tretinoin. They are seeking others' experiences with tretinoin for hair loss.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

The user experienced hair loss after using minoxidil and plans to document their recovery over six months with bi-weekly photos. They aim to regain their hair by following specific routines.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

A user experienced hair thinning after resuming Minoxidil following a 3-month hiatus, despite using a mix of RU58841 and Minoxidil with dutasteride. They seek others' experiences with stopping and restarting Minoxidil.

The user is experiencing hair loss despite using finasteride and Rogaine, with conflicting diagnoses from different hospitals. One suggests no hair loss, while another recommends continuing medication; a suggestion to see a dermatologist for proper assessment is given.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

Microneedling and tretinoin may need to be continued indefinitely to maintain minoxidil's effectiveness for hair loss. The user is aware that stopping minoxidil will result in losing its benefits.

The post argues that Post-Finasteride Syndrome (PFS) is likely not real and suggests symptoms may be due to mental health issues or the nocebo effect. The conversation includes personal experiences with finasteride, highlighting both positive and negative effects, and emphasizes consulting doctors and using reliable sources for medication.

The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.